Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Invasive Pneumococcal Disease Clinical Trial

Official title:
A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use

Status Completed

Clinical Trial Summary

This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

Clinical Trial Description

No sampling as no subjects are enrolled ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01128439
Study type	Observational
Source	Pfizer
Contact
Status	Completed
Phase
Start date	July 2010
Completion date	April 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00853749` - Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine	Phase 3
Completed	`NCT00227188` - Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.	N/A
Recruiting	`NCT00885625` - 7-valent Pneumococcal Conjugated Vaccination	Phase 4
Completed	`NCT04464291` - An Epidemiological Survey to Establish the Spectrum of Circulating Serotypes of S. Pneumoniae, in Patients Older 18 Years	N/A
Completed	`NCT01083459` - Impact of PCV on Disease and Colonization Among Native American Communities	N/A
Completed	`NCT00371878` - Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection	Phase 4